NuScale
SMR
$9.21
-0.97%
NuScale Power Corporation is a developer of proprietary small modular reactor (SMR) technology, operating within the Renewable Utilities industry. The company is a pioneer and leader in the nascent SMR market, aiming to deliver scalable, carbon-free nuclear power through its standardized VOYGR power plants and E2 Centers. The current investor narrative is dominated by extreme volatility and a high-stakes debate between the long-term promise of its technology and near-term financial distress, as recent news highlights disappointing quarterly revenue, project delays, massive cash burn, and a steep stock decline, forcing investors to weigh a potential decade-long wait for commercialization against severe liquidity risks.…
SMR
NuScale
$9.21
Related headlines
Investment Opinion: Should I buy SMR Today?
Rating: Sell. The core thesis is that NuScale represents an excessively risky and overvalued call option on a distant future, with near-term financial distress and a broken technical picture overwhelming its long-term potential.
Supporting evidence is overwhelmingly negative. The valuation is detached from reality at a PS ratio of 73.7x, compared to profitable utilities trading in the low single digits. Revenue growth is not just slow but collapsing, down 94.7% YoY. Profitability is non-existent, with a net margin of -11.3% and gross margins turning negative. While the balance sheet shows zero debt and a strong current ratio of 4.3, this is a temporary reprieve against a cash burn rate that will necessitate highly dilutive financing long before revenue materializes. Analyst sentiment is mixed but leans cautious, with recent actions including a 'Sell' from Citigroup and 'Neutral' from UBS and Goldman Sachs.
The two biggest risks that could further invalidate any bull thesis are 1) a acceleration in cash burn forcing an equity raise below $10 per share, and 2) a formal delay of its first commercial project beyond current estimates. This Sell rating would only be downgraded further (to a Strong Sell) on a breach of the $9.14 low with high volume. It would upgrade to a Hold only if the company announces a major, fully-funded government or utility partnership that extends its runway to 2030+ without dilution, coupled with a stabilization of the stock above $12. The stock is profoundly overvalued relative to any rational assessment of its current financials and near-term prospects.
Sign up to view all
SMR 12-Month Price Forecast
The AI assessment is bearish based on the severe disconnect between valuation and fundamentals, coupled with an accelerating cash burn and broken price trend. The stock is priced as a lottery ticket, but the odds of winning are long and the cost of the ticket (the current market cap) is too high given the near-certainty of further dilution. Confidence is medium (not high) because the unique nature of its technology and the macro tailwinds for nuclear power introduce a non-zero chance of a positive binary event. The stance would upgrade to neutral only upon evidence of a secured, fully-funded path to first revenue that does not require massive equity dilution at current prices.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on NuScale's 12-month outlook, with a consensus price target around $11.97 and implied upside of +30.0% versus the current price.
Average Target
$11.97
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$7 - $12
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, and the available data shows revenue and EPS estimates but not explicit price targets or consensus ratings. The institutional ratings data reveals a mixed but cautious sentiment, with recent actions including a 'Sell' from Citigroup, 'Neutral' from UBS and Goldman Sachs, 'Sector Perform' from RBC Capital, and 'Buy' or 'Overweight' from Canaccord Genuity and Cantor Fitzgerald; this distribution suggests high uncertainty and a lack of strong bullish conviction. The wide dispersion in analyst views—from Sell to Buy—signals profound disagreement on the company's path and timeline, with the low targets likely pricing in further dilution or project failure, while the high targets assume successful technology deployment and multi-year revenue acceleration; this extreme uncertainty, coupled with the stock's high beta, makes price discovery highly volatile and dependent on binary news flow rather than fundamental metrics.
Bulls vs Bears: SMR Investment Factors
The investment debate for NuScale is a stark battle between long-term technological promise and near-term financial distress. The bear case currently holds stronger evidence, grounded in catastrophic revenue decline, massive cash burn, an extreme valuation, and a stock price in freefall. The single most important tension is the race against time: whether the company's $2.9 billion market cap and zero-debt balance sheet provide enough runway to survive the 5-10 year journey to meaningful revenue before investor patience and capital are exhausted. The bull thesis rests entirely on the successful, timely, and profitable commercialization of its SMR technology—a binary outcome with a low probability of success but potentially enormous payoff.
Bullish
- Pioneer in Nascent SMR Market: NuScale is a first-mover in the small modular reactor market, a technology with significant long-term potential for scalable, carbon-free power. Its proprietary VOYGR plant design is based on established nuclear principles, potentially reducing regulatory and technical risk compared to novel reactor designs. This leadership position is the core of its speculative valuation.
- Strong Balance Sheet Liquidity: The company has a robust current ratio of 4.3 and carries zero debt, providing a crucial buffer against near-term operational headwinds. This liquidity is essential for funding its multi-year development runway without the immediate pressure of debt covenants or refinancing risk that plagues many pre-revenue companies.
- Analyst Revenue Estimates Imply Massive Growth: Analyst consensus estimates forecast average revenue of $1.21 billion, representing a monumental leap from the current quarterly run-rate of $1.8 million. This expectation, while speculative, underpins the long-term investment thesis that successful commercialization could unlock a multi-billion dollar revenue stream, potentially beginning in the 2030s.
- Regulatory Tailwinds for Nuclear Power: Geopolitical energy security concerns and the AI industry's power demands are creating a favorable macro environment for next-generation nuclear solutions. Recent news highlights how oil price volatility is reshaping the energy trade, potentially accelerating demand for SMRs as a stable, carbon-free baseload power source.
Bearish
- Catastrophic Revenue Collapse & Cash Burn: Q4 2025 revenue collapsed 94.7% year-over-year to just $1.8 million, indicating no stable revenue stream. Concurrently, the company burned -$203.7 million in operating cash flow in the latest quarter and -$460.1 million over the trailing twelve months, rapidly depleting its cash reserves with no internal generation in sight.
- Extreme Valuation Detached from Fundamentals: The stock trades at a trailing Price-to-Sales ratio of 73.7x, an astronomical multiple that prices in a decade of flawless execution. This valuation is entirely based on long-term optionality, leaving the stock highly vulnerable to de-rating if commercialization timelines slip or capital costs rise, as evidenced by its 76.5% six-month decline.
- Severe Technical Downtrend & Volatility: The stock is in a severe downtrend, down 76.5% over six months and trading at just 16% of its 52-week high-to-low range. With a beta of 2.28, it is more than twice as volatile as the market, and a breach of the $9.14 52-week low could trigger another leg down, reflecting intense selling pressure and negative sentiment.
- Project Delays & Commercialization Timeline Risk: Recent news highlights critical project delays and a commercialization timeline that may extend to 2033 or beyond. The company's path to revenue is long, uncertain, and capital-intensive, requiring patient capital while facing execution risk, potential cost overruns, and competitive or regulatory hurdles that could further delay first power.
SMR Technical Analysis
The stock is in a severe and sustained downtrend, having declined 76.5% over the last six months and 38.0% over the past year. With a current price of $9.21, it is trading near the very bottom of its 52-week range, at just 16% of the distance from its 52-week low of $9.14 to its high of $57.42, indicating the stock is in deep distress territory and pricing in significant fundamental deterioration. Recent momentum remains intensely negative, with the stock down 25.6% over the past month and 55.1% over the last three months, confirming the bearish trend is accelerating rather than showing any signs of reversal; this is starkly illustrated by its relative strength of -26.1 against the S&P 500's 0.5% gain over the same period. Key technical support is the absolute 52-week low of $9.14, a breach of which could trigger another leg down, while any meaningful recovery would face initial resistance in the $12-$15 range from recent consolidation; the stock's extreme volatility is quantified by a beta of 2.28, meaning it is more than twice as volatile as the broader market, which necessitates outsized risk tolerance for any position.
Beta
2.28
2.28x market volatility
Max Drawdown
-82.9%
Largest decline past year
52-Week Range
$9-$57
Price range past year
Annual Return
-38.0%
Cumulative gain past year
| Period | SMR Return | S&P 500 |
|---|---|---|
| 1m | -25.6% | +2.6% |
| 3m | -55.1% | -2.3% |
| 6m | -76.5% | +2.6% |
| 1y | -38.0% | +27.3% |
| ytd | -43.5% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SMR Fundamental Analysis
Revenue growth is highly erratic and currently collapsing, with Q4 2025 revenue of just $1.8 million representing a catastrophic 94.7% year-over-year decline; this follows a volatile pattern from $34.2 million in Q4 2024 to $8.2 million in Q3 2025, indicating the business lacks a stable, recurring revenue stream as it remains in a pre-commercial development phase. The company is deeply unprofitable, posting a net loss of $50.8 million in Q4 2025 and a gross margin of -3.4% for that quarter, though the gross margin has fluctuated wildly from 91.1% in Q4 2024 to 32.9% in Q3 2025, highlighting the immaterial and non-representative nature of current revenues against a massive fixed cost base; the net margin stands at -11.3% on a trailing basis, but losses are substantial and cash burn is the primary concern. The balance sheet shows a strong current ratio of 4.3 and zero debt, providing near-term liquidity, but this is overshadowed by a massive annual cash burn, with free cash flow over the trailing twelve months at -$460.1 million and an operating cash flow of -$203.7 million in the latest quarter, indicating the company is rapidly consuming its cash reserves to fund development with no internal cash generation in sight.
Quarterly Revenue
$1808000.0B
2025-12
Revenue YoY Growth
-0.94%
YoY Comparison
Gross Margin
-0.03%
Latest Quarter
Free Cash Flow
$-460117999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SMR Overvalued?
Given the company's consistent net losses, the primary valuation metric is the Price-to-Sales (PS) ratio. The trailing PS ratio is an astronomical 73.7x, while the forward PS ratio cannot be reliably calculated but would be even higher based on depressed revenue estimates, reflecting a market valuation entirely detached from current financials and based purely on long-term optionality. There is no meaningful peer comparison for a pre-revenue SMR developer within standard industry averages; the extreme PS multiple underscores that the stock is priced as a speculative call option on future technology adoption rather than a going concern. Historically, the stock's own valuation has compressed dramatically from a PS ratio of 1283.2x at the end of Q4 2025 to the current 73.7x, indicating a massive de-rating as the market has shifted focus from long-term potential to near-term survival risk; however, even at this lower level, the valuation remains at the extreme high end of any rational spectrum, suggesting the market still ascribes significant, albeit diminished, probability to a successful outcome.
PE
-6.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -75x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and immediate. The company's revenue is immaterial and collapsed 94.7% YoY in Q4 2025 to $1.8 million, demonstrating it lacks a viable business model today. Gross margin turned negative (-3.4%) in the same quarter, highlighting the non-representative nature of current sales against a massive fixed cost base. The paramount risk is liquidity: with an operating cash flow burn of -$203.7 million last quarter and a TTM free cash flow burn of -$460.1 million, the company is consuming cash reserves at an unsustainable rate to fund development, with no internal cash generation for years.
Market & Competitive Risks center on its speculative valuation and sector volatility. The trailing PS ratio of 73.7x is astronomically high, pricing in flawless execution over a decade; any delay or cost overrun could trigger massive multiple compression, as seen in its derating from a PS of 1283.2x. The stock's beta of 2.28 means it is more than twice as volatile as the market, amplifying downside during risk-off periods. As a pioneer, it also faces regulatory uncertainty, potential competitive disruption from other SMR developers, and the risk that alternative clean energy technologies advance more quickly.
The Worst-Case Scenario involves a 'death spiral' of dilution and project failure. A sequence of further project delays, escalating development costs, and inability to secure additional non-dilutive funding (like government grants or partner capital) would force the company to raise equity at severely depressed prices, massively diluting existing shareholders. This could be triggered by a key partnership falling through or a critical regulatory setback. The realistic downside from the current $9.21 price is a breach of the $9.14 52-week low and a fall towards the $5-$7 range, representing a potential 35-45% loss, as the market prices in a high probability of equity raises or even bankruptcy before commercialization.
FAQ
The key risks are, in order of severity: 1) Liquidity & Dilution Risk: The company burns ~$200M per quarter and will need to raise equity, likely at much lower prices, within 12-18 months. 2) Commercialization Timeline Risk: Revenue is not expected until the 2030s, and any delay could be catastrophic for the stock. 3) Valuation Compression Risk: The current PS ratio of 73.7x leaves immense room for de-rating on bad news. 4) Execution & Regulatory Risk: Building first-of-a-kind nuclear plants involves complex engineering, supply chain, and regulatory hurdles that could cause cost overruns or delays.
The 12-month forecast is highly uncertain but skewed to the downside. Our base case (50% probability) sees the stock range-bound between $8 and $12, as dilution fears cap rallies and its zero-debt balance sheet provides some floor. The bear case (35% probability) targets $4-$7, triggered by a dilutive capital raise or project delay. The bull case (15% probability) sees a rally to $25-$35 on a transformative partnership announcement. The most likely scenario is the base case, which assumes the company continues to 'muddle through' with high cash burn but avoids an immediate crisis.
SMR is profoundly overvalued by any conventional metric. Its trailing Price-to-Sales ratio of 73.7x is astronomical; for context, mature, profitable utilities trade at PS ratios in the 1x-3x range. The market is valuing the company at $2.9 billion based on future revenue estimates that are at least 5-7 years away and subject to significant execution risk. This valuation implies the market is assigning a high probability to a successful, multi-billion dollar revenue outcome that is far from certain. The stock's 76.5% collapse over six months is a direct result of this valuation compressing as reality sets in.
For the vast majority of investors, SMR is not a good stock to buy. It is an exceptionally high-risk, speculative asset with a valuation (PS ratio of 73.7x) that prices in perfection over the next decade. The company is burning over $460 million in cash annually with no revenue in sight, making future dilution highly probable. It could only be considered a 'good buy' for a very specific investor: one with venture capital risk tolerance, a 10-year time horizon, a portfolio sized to absorb a total loss, and a strong conviction in the inevitability of SMR adoption with NuScale as the winner.
SMR is unsuitable for short-term trading for all but the most sophisticated (and lucky) traders, given its extreme volatility (beta of 2.28) and dependence on binary news flow. By its nature as a pre-revenue developer, it is ostensibly a long-term investment, but the 'long-term' here is measured in decades, not years. The company pays no dividend and offers no earnings visibility. If an investor has a thesis in the technology, the minimum suggested holding period is 7-10 years, with the understanding that the position will likely be diluted multiple times along the way and could still result in a total loss.